Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Histone H3-mutant gliomas are deadly brain tumors characterized by a dysregulated epigenome and stalled differentiation. In contrast to the extensive datasets available on tumor cells, limited information exists on their tumor microenvironment (TME), particularly the immune infiltrate. Here, we characterize the immune TME of H3.3K27M and G34R/V-mutant gliomas, and multiple H3.3K27M mouse models, using transcriptomic, proteomic and spatial single-cell approaches. Resolution of immune lineages indicates high infiltration of H3-mutant gliomas with diverse myeloid populations, high-level expression of immune checkpoint markers, and scarce lymphoid cells, findings uniformly reproduced in all H3.3K27M mouse models tested. We show these myeloid populations communicate with H3-mutant cells, mediating immunosuppression and sustaining tumor formation and maintenance. Dual inhibition of myeloid cells and immune checkpoint pathways show significant therapeutic benefits in pre-clinical syngeneic mouse models. Our findings provide a valuable characterization of the TME of oncohistone-mutant gliomas, and insight into the means for modulating the myeloid infiltrate for the benefit of patients.
Description
Acknowledgements: This work was supported by a Large-Scale Applied Research Project grant from Génome Quebec, Genome Canada, the Government of Canada, and Ministère de l’Économie et de l’Innovation du Québec, with the support of the Ontario Research Fund through funding provided by the Government of Ontario to N.J. and C.L.K. Additional funding support was provided by the We Love You Connie Foundation, Fondation Charles-Bruneau (to N.J), National Institutes of Health (NIH) grant P01-CA196539 (to N.J); Canadian Institutes of Health Research (CIHR) grants FDN-154307 (to N.J.) and PJT-156086 (to C.L.K.); Canadian Cancer Society (CCSRI) grant 705182 and a Fonds de Recherche du Québec–Santé (FRQS) salary award (to C.L.K.); the Fonds de recherche du Québec–Santé, Génome Québec, and the Cancer Research Society (to C.L.K.); NSERC RGPIN-2016-04911 (to C.L.K.); CFI Leaders Opportunity Fund 33902 (to C.L.K.); and Digital Research Alliance of Canada Resource Allocation Projects WST-164-AB and MJD-574-AC. Data analyses were enabled by computing and storage resources provided by Digital Research Alliance of Canada and Calcul Québec. N.J. is a member of the Penny Cole Laboratory and holds a Canada Research Chair (CRC) Tier 1 in Pediatric Oncology from CIHR. This work was supported in part by the Stand Up To Cancer grant “Immuno-modulation to Treat Poor-Prognosis Pediatric Brain Tumors”. M.P. is supported by start-up funding from the Cancer Research UK Children’s Brain Tumor Center of Excellence; Brain Research UK Project Grant 202021-28; Brain Tumor Charity Quest for Cures Collaborative Discovery Teams Award GN-000728; Great Ormond Street Hospital Children’s Charity Project Grant V4020; a donation from the family of Emily Parsons; and a Cancer Research UK Career Establishment Award RCCCEA-May22\100003. L.K. is supported by Yale University start-up funds, Yale Program for the Promotion of Interdisciplinary Science, Binational Science Foundation award number 2019075 and NIH grants R21TR002639, R21HD102565, and R01AI171980. Figure 3A-B; 4A; 5C and 6E-F, created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. We would like to thank Bristol-Meyer Squibb for kindly providing mouse PD1 inhibitor (4H2) used in this study. The authors are thankful for the technical support from Single Cell and Imaging Mass Cytometry Platform (SCIMAP) and Histology core facilities from the Rosalind and Morris Goodman Cancer Institute (GCI), Life Sciences Complex at McGill University, McGill Genome Center, RI-MUHC Histology Platform and the Segal Cancer Center Research Pathology Facility, Jewish General Hospital.
Funder: We Love You Connie Foundation, Fondation Charles-Bruneau (to N.J), National Institutes of Health (NIH) grant P01-CA196539 (to N.J); Canadian Institutes of Health Research (CIHR) grants FDN-154307 (to N.J.) and PJT-156086 (to C.L.K.); Canadian Cancer Society (CCSRI) grant 705182 and a Fonds de Recherche du Québec – Santé (FRQS) salary award (to C.L.K.); the Fonds de recherche du Québec - Santé, Génome Québec, and the Cancer Research Society (to C.L.K.); NSERC RGPIN-2016-04911 (to C.L.K.); CFI Leaders Opportunity Fund 33902 (to C.L.K.); and Digital Research Alliance of Canada Resource Allocation Projects WST-164-AB and MJD-574-AC. Brain Research UK Project Grant 202021-28; Brain Tumour Charity Quest for Cures Collaborative Discovery Teams Award GN-000728; Great Ormond Street Hospital Children’s Charity Project Grant V4020; a donation from the family of Emily Parsons; and a Cancer Research UK Career Establishment Award RCCCEA-May22\100003. L.K. is supported by Yale University start-up funds, Yale Program for the Promotion of Interdisciplinary Science, Binational Science Foundation award number 2019075 and NIH grants R21TR002639, R21HD102565, and R01AI171980.
Journal Title
Conference Name
Journal ISSN
2041-1723